G MEDICAL UPDATES ON PATIENT ENROLLMENT GROWTH FOR ITS HOME MONITORING SERVICES OF 194% FROM JANUARY THROUGH APRIL 2023, AS COMPARED TO THE SAME PERIOD IN 2022
April 18 2023 - 9:26AM
G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”
or “G Medical"), a global leader in next-generation mobile health
(mHealth) and digital health, is excited to report that patient
enrollment has grown in its home monitoring services by 194%
between January and April of 2023, as compared to the same period
last year. The increase is due to growing demand for homecare
monitoring. As previously announced, in the first quarter of 2023,
G Medical signed an agreement with AdventHealth of Central Florida
(“AdventHealth”), an operator of 20 hospitals and emergency rooms.
AdventHealth experiences on average 5.7 million patient visits per
year. G Medical also recently signed an agreement with MiCare Path
to integrate MiCare Path’s software platform and visualization
tools to its devices. By integrating MiCare Path’s virtual health
solutions with G Medical’s global health solutions and devices,
physicians and patients will benefit from the next-generation care
driving better outcomes for patients across all services. The G
Medical collaboration will allow for a total remote patient
monitoring (RPM) and remote therapeutic monitoring (RTM) solution
from service to exceptional future solutions. The Company looks
forward to announcing additional key agreements in 2023.
In line with its strategy of providing remote
health services, in the second half of 2022, G Medical entered the
at home laboratory testing market by developing 31 test kits for
use by consumers at its CLIA-certified laboratory in Austin, Texas,
which is now fully operational. G Medical expects that in the third
quarter of 2023 consumers will be able to purchase these kits at
retail stores or via online purchase. From the comfort and privacy
of their own home, consumers will be able to use its kits to
collect their own saliva, urine or blood sample and send it by mail
to its lab in Austin for testing and analysis and receive complete
report within 48 hours.
|
Test name |
Parameters Analyzed |
1. |
Men’s Health |
Estradiol, Progesterone, Testosterone, DHEA, Cortisol (Morning,
noon, Evening, Bedtime), TSH, fT3, fT4, TPO |
2. |
Women’s Health |
Estradiol, Progesterone, Testosterone, DHEA, Cortisol (Morning,
noon, Evening, Bedtime), TSH, fT3, fT4, TPO |
3. |
Metabolism |
TSH, Free Testosterone, Cortisol |
4. |
Thyroid |
TSH, fT3, fT4 |
5. |
Testosterone |
Free testosterone |
6. |
Vitamin D |
Vitamin D level |
7. |
Inflammation |
HS-CRP, Vitamin D level |
8. |
Heart Health |
Cholesterol, LDL, HDL, Triglycerides, HS-CRP, HbA1c |
9. |
Women’s Fertility |
Estradiol, LH, FSH, Testosterone |
10. |
Sleep and Stress |
Cortisol, Melatonin, DHEA |
11. |
HPV |
HPV genotypes - 6, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,
68 |
12. |
Postmenopause |
Estradiol, Progesterone |
13. |
Perimenopause |
Estradiol, FSH, Progesterone |
14. |
FIT colon cancer |
Blood in stool |
15. |
HgA1C |
HbA1c |
16. |
Indoor/Outdoor allergies |
IgE reactivity |
17. |
Skin Health |
Estradiol, Progesterone, Testosterone, DHEA, Morning Cortisol, TSH,
Vitamin D |
18. |
Weight loss |
Estradiol, Progesterone, Testosterone, DHEA, Morning Cortisol, TSH,
HbA1c, HS-CRP,Vitamin D |
19. |
Comprehensive Fitness |
DHEA, Morning Cortisol, Testosterone, TSH, HS-CRP, Vitamin D |
20. |
Monkeypox |
Orthopoxvirus DNA |
21. |
STD - male (7 diseases panel) |
Chlamydia, Gonorrhea, Hepatitis C, HIV (HIV1, HIV2, P24), Syphilis,
Trichomoniasis |
22. |
STD - female (7 diseases panel) |
Chlamydia, Gonorrhea, Hepatitis C, HIV (HIV1, HIV2, P24), Syphilis,
Trichomoniasis |
23. |
Chlamydia & Gonorrhoea |
Chlamydia & Gonorrhoea |
24. |
Trichomoniasis |
Trichomoniasis |
25. |
Hepatitis C Antibody |
Hepatitis C Antibody |
26. |
HIV 1&2 |
HIV 1&2, P24 |
27. |
Trep-Sure - syphilis total antibody |
syphilis total antibody |
28. |
Food sensitivity – 96 types |
IgG reactivity |
29. |
Food sensitivity – 208 types |
IgG reactivity |
30. |
Omega 3 |
Omega-3 Fatty Acids• Alpha-Linolenic Acid (ALA)•
Eicosapentaenoic Acid (EPA)• Docosapentaenoic Acid (DPA)•
Docosahexaenoic Acid (DHA) |
31. |
Mother’s milk |
DHA |
The Company has also recently completed an
equity capital raise of $9.6 million dollars in order to fund its
continued growth. President and Chief Executive Officer, Dr. Yacov
Geva participated in this raise personally with a $1 million
investment, further confirming his own conviction in the continued
growth of G Medical. "I firmly believe that G Medical's
continued growth evidences its leadership in providing wholistic,
convenient and affordable care to everyone." said Dr. Geva.
About G Medical Innovations Holdings
Ltd.
G Medical Innovations Holdings Ltd. is a
healthcare company engaged in the development of next generation
mHealth and telemedicine solutions and monitoring service
platforms. The Company’s solutions and services can empower
consumers, patients, and providers to better monitor, manage and
improve clinical and personal health outcomes, especially for those
who suffer from cardiovascular disease (or CVD), pulmonary disease,
and diabetes. The Company’s current product lines consist of its
Prizma medical device (or Prizma), a clinical-grade device that can
transform almost any smartphone into a medical monitoring device,
enabling both healthcare providers and individuals to monitor,
manage and share a wide range of vital signs and biometric
indicators; its Extended Holter and Monitoring Cardiac Telemetry
Patch services, utilizing a multi-channel patient-worn biosensors,
with algorithms for real time analysis and transmission that
captures electrocardiography (i.e. ECG) data continuously,
including QT Syndrome Prolongation Detection. In addition, the
Company is developing its Wireless Vital Signs Monitoring System
(or VSMS), which is expected to provide full, continuous, and
real-time monitoring of a wide range of vital signs and biometrics.
Its monitoring services include provision of Independent Diagnostic
Testing Facility (i.e., IDTF) monitoring services and private
monitoring services. In the second half of 2022, the Company
expanded its business activities into a new business area, at-home
laboratory testing kits. In the third quarter of 2023, the Company
expects that users will be able to purchase a sample collection kit
at retail stores or online and collect their sample from the
comfort and privacy of their home and send it via mail to the
Company’s certified lab for analysis. The Company has developed 31
types of tests kits which can test a wide range health issued
related to hormones, sexual transferred disease, colon cancer,
nutrition, food sensitivities and allergies. In addition, the
Company’s pipeline includes development of additional kits for drug
detection, heavy metal and toxicology. Data received from both
vital signs and lab tests reflects the vision of the Company which
is to allow users to create their personal electronic medical
records and manage their health in one location which is available
for them anywhere and anytime without dependency on any medical
organization.
For more information about G Medical innovations,
visit https://gmedinnovations.com/.
Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, G Medical Innovations is
using forward-looking statements when it discusses its
collaborations with strategic partners, including the services to
be provided by the Company as part of the collaboration with
AdventHealth and the benefits of its collaboration with MiCare
Path; its expectation that in the third quarter of 2023 consumers
will be able to purchase its at home test kits at retail stores or
via online purchase; its expectation that consumers will be able to
use its kits to collect samples at home and receive a complete
report within 48 hours of mailing the sample to its lab; the
continued growth of G Medical; and that its continued growth
evidences its leadership in providing wholistic, convenient and
affordable care to everyone. Because such statements deal with
future events and are based on the Company’s current expectations,
they are subject to various risks and uncertainties, and actual
results, performance, or achievements of G Medical Innovations
could differ materially from those described in or implied by the
statements in this press release. The forward-looking statements
contained or implied in this press release are subject to other
risks and uncertainties, including those discussed under the
heading “Risk Factors” in the Company’s Registration Statement on
Form F-1, as amended, filed with the Securities and Exchange
Commission (“SEC”) on March 24, 2023, which is available on the
SEC’s website, www.sec.gov. Except as otherwise required by law, G
Medical Innovations undertakes no obligation to publicly release
any revisions to these forward-looking statements to reflect events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events. References and links to websites have been
provided as a convenience, and the information contained on such
websites is not incorporated by reference into this press
release.
Investor Relations Contact
G Medical Innovations service@gmedinnovations.com
G Medical Innovations (NASDAQ:GMVD)
Historical Stock Chart
From Mar 2024 to Apr 2024
G Medical Innovations (NASDAQ:GMVD)
Historical Stock Chart
From Apr 2023 to Apr 2024